Cost of albuterol inhalers set to triple in 2008
Mar 30, 2007 - The cost of albuterol asthma inhalers in the USA is set to triple after 2008, when inhalers that release environmentally damaging chlorofluorocarbons (CFCs) will be banned, say researchers.
Leslie Hendeles (University of Florida, Gainesville, USA) and team explain that albuterol is the most widely used drug for short-term relief of symptoms related to bronchospasm in patients with asthma and chronic obstructive pulmonary disease.
After 2008, CFC propellants in albuterol inhalers will be replaced by hydrofluoroalkane (HFA) propellants. The researchers estimate that HFA inhalers will cost three times as much as CFC inhalers, at least until generic versions become available.
Hendeles et al report that Americans will need to spend an additional US$1.2 billion (€900 million) a year on the three patented inhaler brands containing HFA propellants. Cheaper, generic versions will probably not be available until after 2012.
Patients who pay for their medication will probably be hit hardest, paying on average $312 (€233) more per year. But the healthcare bills of all inhaler users will likely be higher for at least a few years as a result of the ban.
Hendeles et al conclude after reviewing previous research that the HFA inhalers are as effective as CFC inhalers, but do differ in some important ways. For example, only one of the three brands of HFA inhaler has a counter to show users how many doses they have left.
“There isn’t any reliable way of estimating when they’re going to run out,” said Hendeles.
The researchers also mention in the New England Journal of Medicine that some HFA inhalers tend to clog more easily than CFC inhalers. Patients must therefore remove their metal canisters once a week and clean the plastic actuators with warm water.
Two brands of HFA inhaler also contain ethanol, and so may not be appropriate for some patients due to their religious beliefs.
Hendeles added: “There will undoubtedly be some people who are absolutely certain [the HFA inhaler] doesn’t work as well,” but he stressed that patient education is the key to proper care.
Read More
